Salidroside|cas 10338-51-9|DC Chemicals|Price|Buy

Cas No.:	10338-51-9
SMILES:	O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1OCCC2=CC=C(O)C=C2
Formula:	C₁₄H₂₀O₇
M.Wt:	300.3
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Salidroside is a prolyl endopeptidase Inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling.
Target:	mTOR
In Vivo:	Salidroside is a natural antioxidant extracted from medicinal food plant Rhodiola rosea. Salidroside (100 mg/kg/day) shows strong glucose lowering effect on db/db mice which is similar to effect of Metformin (200 mg/kg/day). For this reason, the dose of 100 mg/kg/day salidroside is used[4].
In Vitro:	Salidroside (100 μM) inhibits prolyl endopeptidase (PEP) activity (10.6±1.9%). Prolyl endopeptidase is an enzyme that plays a role in the metabolism of proline-containing neuropeptidase which is recognized to be involved in learning and memory[1]. Salidroside, one of the major phenylpropanoid glycosides found in R. rosea L, is consumed almost daily as a nutritional supplement in many countries and has been identified possessing potential anti-fatigue and anoxia,anti-aging, and anti-Alzheimer's disease activities. Salidroside can improve muscle nutrition via increasing mTOR, p-mTOR, and MyHC expression[2]. SH-SY5Y cells are exposed to 0-600 μM MPP+ for 12-48 h and the results show that MPP+ results in a significant decrease of cell viability in a concentration and time-dependent manner. Cells are pretreated with 25-100 μM Salidroside (Sal) for 24 h and then exposed to 500 μM MPP+ for an additional 24 h. Salidroside concentration-dependently prevents MPP+-induced decrease of cell viability. Annexin V/PI staining is a common method for the detection of apoptotic cell. Salidroside significantly decreases the number of Annexin V/PI-stained cells treated by MPP+ which is in a concentration-dependent manner. Apoptotic cell could also be morphologically evaluated by Hoechst staining. In Hoechst staining, apoptotic cells are characterized by reduced nuclear size, chromatin condensation, intense fluorescence, and nuclear fragmentation. Salidroside notably inhibits MPP+-induced increase of chromatin condensation, intense fluorescence, and nuclear fragmentation in SH-SY5Y cells[3].
Cell Assay:	SH-SY5Y cells are seeded in 96-well plates at 1×104 cells per well. After the treatment with Salidroside (25-100 μM) and MPP+, cell viability is measured by MTT assay. Briefly, cells are incubated with 500 μg/mL MTT at 37°C for 4 h. After that, the medium is removed and 150 μL DMSO is added and shaking is conducted for 10 min. Absorbance is measured at 570 nm in a microplate reader and the results are expressed as folds of control[3].
Animal Administration:	Mice[4] The 4-week-old male C57BL/6 mice are fed a high-fat diet (HFD) (n=16) or normal chow diet (n=8). After 10 weeks of the HFD, salidroside intervention (100 mg/kg/day) is initiated by gavage once a day for 5 weeks. The control groups are given vehicle (saline). The 4-week-old male C57Bl/KsJ (BKS) mice (wild type, n=8) and BKS.Cg-Dock7m +/+ Leprdb/J (db/db) mice (n=16) are used. Salidroside (100 mg/kg/day) is administrated orally by gavage once a day for 5 weeks. The control groups are given vehicle (saline). Fasting blood glucose and body weight of mice are monitored every 5 days. Glucose measurements are performed on blood drawn from the tail vein using a Glucometer.
References:	[1]. Fan W, et al. Prolyl endopeptidase inhibitors from the underground part of Rhodiola sachalinensis. Chem Pharm Bull (Tokyo). 2001 Apr;49(4):396-401. [2]. Chen X, et al. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activatingmTOR signalling. J Cachexia Sarcopenia Muscle. 2016 May;7(2):225-32. [3]. Wu L, et al. Salidroside Protects against MPP+-Induced Neuronal Injury through DJ-1-Nrf2 Antioxidant Pathway. Evid Based Complement Alternat Med. 2017;2017:5398542. [4]. Ju L, et al. Salidroside, A Natural Antioxidant, Improves β-Cell Survival and Function via Activating AMPK Pathway. Front Pharmacol. 2017 Oct 18;8:749.

Cat. No.	Product name	Field of application
DC31079	Abarelix	Abarelix is a synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC79856	EVT0185	EVT0185 is an orally active ATP citrate lyase (ACLY) inhibitor. EVT0185 is converted to a CoA thioester in the liver by SLC27A2 and interacts with the CoA-binding site of ACLY. EVT0185-CoA inhibits ACLY activity with an IC50 of 2.5 μM. EVT0185 can phenocopy the immune and antitumour effects of genetic ACLY deletion. EVT0185 can increase tumour-infiltrating B cells and chemokine CXCL13 levels. EVT0185 can be used for the research of cancer, such as hepatocellular carcinoma (HCC).
DC79609	NCGC00685960	NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 < 10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research.
DC79112	Simepdekinra	Simepdekinra (Compound 221) is a IL-17A modulator with IC50s ≤10  nM and 10-100 nM for IL-17A/A HEK-Blue and IL-17A/F HEK-Blue cells. Simepdekinra can be used for inflammatory diseases such as psoriasis, ankylosing spondylitis and psoriatic arthritis research.
DC78751	RSL3-NH2	RSL3-NH2 is a GPX4 inhibitor and Ferroptosis inducer. RSL3-NH2 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs).
DC77831	Vicadrostat	Vicadrostat (compound 29 A) is a potent and selective inhibitor of aldosterone synthase(CYP11B2) with an IC50 of 16 nM. It exhibits potential in renal disease, diabetic nephropathy, cardiovascular diseases and fibrotic disorder research.
DC77813	Zeltociclib	Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects.
DC77784	UNC10013	UNC10013 is a SETDB1 allosteric modulator that forms a covalent bond with Cys385 in the 3TD domain, exhibiting negative allosteric regulatory activity. It has a kinact/KI value of 1.0 × 106 M-1*s-1. UNC10013 effectively disrupts SETDB1-mediated Akt methylation and holds potential value for research in cancer and neurodegenerative diseases.
DC77740	T0080	T0080 is a FPR-1 antagonist. T0080 reduces the cell apoptosis, inhibits ROS production and pro-inflammatory cytokines (TNF-α and IL-1β) from plaque macrophages, which attenuates atherosclerotic progression in ApoE−/− mice.